Furthermore, scientists have evaluated the direct immunotherapeutic impact of the anti-CD20 mAb rituximab on human chronic lymphocytic leukemia (CLL) cells in response to the co-administration of CXCL12/CXCR4 inhibitors (99, 100). This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.